LEE WILLIS C 4/A
4/A · Emmaus Life Sciences, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4/AAmended
LEE WILLIS C
DirectorVice Chairman & COO
Transactions
- Purchase
Common stock, $0.001 par value
2023-08-25$0.21/sh+6,500$1,365→ 37,100 total(indirect: By IRA) - Purchase
Common stock, $0.001 par value
2023-11-29$0.12/sh+36,000$4,320→ 335,724 total - Purchase
Common stock, $0.001 par value
2023-08-31$0.15/sh+6,000$900→ 43,100 total(indirect: By IRA) - Purchase
Common stock, $0.001 par value
2023-11-30$0.12/sh+59,400$7,128→ 395,124 total - Purchase
Common stock, $0.001 par value
2023-11-14$0.12/sh+1,100$132→ 44,200 total(indirect: By IRA) - Purchase
Common stock, $0.001 par value
2023-11-28$0.12/sh+12,000$1,440→ 299,724 total
Holdings
- 241,194(indirect: By IRA)
Common stock, $0.001 par value
Footnotes (2)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4.
- [F2]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive.